<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868010</url>
  </required_header>
  <id_info>
    <org_study_id>1R01HD055525</org_study_id>
    <secondary_id>NIH grant: 1 R01 HD055525-01A2</secondary_id>
    <nct_id>NCT00868010</nct_id>
  </id_info>
  <brief_title>Enhancing Rehabilitation After Stroke</brief_title>
  <acronym>Enhance</acronym>
  <official_title>Donepezil to Promote Functional Recovery Post-stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, randomized, placebo controlled study to determine if donepezil (Aricept)&#xD;
      treatment during rehabilitation after stroke improves functional recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is a leading cause of disability in the US (Thom 2006). The total number of stroke&#xD;
      survivors (currently estimated as 5.5 million Americans) will continue to increase as the&#xD;
      population ages and as the medical management of acute stroke continues to improve. Given&#xD;
      stroke's devastating impact on activities of daily living and the large numbers of Americans&#xD;
      afflicted, improving acute medical rehabilitation outcomes after stroke is of great public&#xD;
      health importance.&#xD;
&#xD;
      Predictors of poor functional recovery post-stroke include impairments in cognition and&#xD;
      motivation. Recent evidence indicates that acetylcholinesterase inhibitors may improve&#xD;
      cognition and motivation; hence, their use post-stroke may lead to improved rehabilitation&#xD;
      outcomes. Our group has demonstrated that use of the acetylcholinesterase inhibitor donepezil&#xD;
      is associated with improved functional recovery in a pilot sample (n = 40) of elderly,&#xD;
      cognitively impaired stroke survivors undergoing inpatient rehabilitation. Specifically, in&#xD;
      this 12 week open-label study, those subjects receiving donepezil experienced a clinically&#xD;
      meaningful 14 point greater improvement on the Functional Independence Measure (FIM) than an&#xD;
      archival comparator group.&#xD;
&#xD;
      Based on these promising pilot study results, we propose a 12-week randomized, double-blind,&#xD;
      placebo-controlled trial (followed by a 12 week off-drug observation period) in order to test&#xD;
      the efficacy of donepezil to promote post-stroke functional recovery in older, cognitively&#xD;
      impaired stroke survivors undergoing inpatient rehabilitation. We will also use this&#xD;
      randomized controlled trial to examine the drug's effect on cognition post-stroke;&#xD;
      specifically, the drug's effect on those cognitive domains (attention/working memory,&#xD;
      information psychomotor speed, and episodic memory) that are relevant to functional outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Independence Measure (FIM)</measure>
    <time_frame>Weekly/12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function (ImPACT battery used to assess attention - working memory continuum, information processing speed, and verbal and visual episodic memory.)</measure>
    <time_frame>Multiple time points over 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>1: donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>donepezil</intervention_name>
    <description>5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.</description>
    <arm_group_label>1: donepezil</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive a placebo pill for 12 weeks if randomized to this treatment.</description>
    <arm_group_label>2. placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female;&#xD;
&#xD;
          2. aged 18 or older;&#xD;
&#xD;
          3. new ischemic stroke within the preceding 30 days; and&#xD;
&#xD;
          4. admitted to the an inpatient facility of the UPMC Institute for Rehabilitation and&#xD;
             Research for post-stroke rehabilitation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. primary hemorrhagic stroke;&#xD;
&#xD;
          2. current use of a cholinomimetic drug including tacrine, donepezil, galantamine, and&#xD;
             rivastigmine;&#xD;
&#xD;
          3. contraindication to AchEi therapy including bradycardia (&lt; 50 bpm), severe asthma or&#xD;
             COPD requiring nebulized medication, and active upper GI bleed or untreated gastric&#xD;
             ulcer;&#xD;
&#xD;
          4. myocardial infarction, poorly controlled congestive heart failure, or coronary bypass&#xD;
             surgery within the last 3 months;&#xD;
&#xD;
          5. current required use of an anticholinergic medication (e.g., for bladder spasm);&#xD;
&#xD;
          6. current aphasia severe enough to prevent valid neuropsychiatric assessment (e.g., a&#xD;
             score &lt; 9 on the Token Test, part I and a score of &lt; 14 (or &lt;80% accuracy) on the&#xD;
             repetition task of the Boston Diagnostic Aphasia Examination);&#xD;
&#xD;
          7. current Major Depressive Episode AND HRSD &gt; 20;&#xD;
&#xD;
          8. current active suicidal ideation, plan, or intent;&#xD;
&#xD;
          9. current mania or hypomania;&#xD;
&#xD;
         10. current psychosis;&#xD;
&#xD;
         11. meeting DMS-IV TR alcohol or substance abuse or dependence criteria within the&#xD;
             preceding 3 months;&#xD;
&#xD;
         12. subject and/or family informant do not speak English;&#xD;
&#xD;
         13. history of a progressive or unstable CNS disease (e.g., multiple sclerosis,&#xD;
             Parkinson's disease, HIV with CNS involvement);&#xD;
&#xD;
         14. medically unstable (determined by review of the subject's medical status with the&#xD;
             treating (clinical) physician and by review of standard blood tests); and&#xD;
&#xD;
         15. history of sensitivity to donepezil;&#xD;
&#xD;
         16. for potential subjects without a pacemaker or implantable defibrillator, exclusion&#xD;
             criteria will include (a) ECG evidence of second or third degree heart block ( b ) ECG&#xD;
             evidence of a tri-fascicular block (LBBB and 1st degree AV Block; RBBB, left anterior&#xD;
             or left posterior hemiblock, and 1st degree AV block) or ( c ) history of syncope&#xD;
             within 1 year with a RBBB or a LBBB.&#xD;
&#xD;
         17. For females of child-bearing age, current pregnancy, plan to become pregnant while on&#xD;
             study drug, or refusal to avoid pregnancy while on study drug.&#xD;
&#xD;
         18. For females of child-bearing age, current breast feeding.&#xD;
&#xD;
         19. suicidal attempt in the past one year,&#xD;
&#xD;
         20. an inpatient admission for depression in the past one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen M Whyte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Kenton</last_name>
    <phone>412-246-5815</phone>
    <email>kentonkd@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hillside Rehabilitation Hospital</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Landgraff, PhD</last_name>
      <phone>330-941-2703</phone>
      <email>nlandgra@cc.ysu.edu</email>
    </contact>
    <investigator>
      <last_name>Nancy Landgraff, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Kenton</last_name>
      <phone>412-246-5815</phone>
      <email>kentonkd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Aizenstein, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen M Whyte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meryl Butters, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ariel Gildengers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordan Karp, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sati Mazumdar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Munin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Reynolds, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Skidmore, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.strokeassociation.org</url>
    <description>American Stroke Association website provides general information regarding stroke and stroke prevention.</description>
  </link>
  <reference>
    <citation>Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 Feb 14;113(6):e85-151. Epub 2006 Jan 11. Erratum in: Circulation. 2006 Apr 11;113(14):e696. Circulation. 2006 Dec 5;114(23):e630.</citation>
    <PMID>16407573</PMID>
  </reference>
  <reference>
    <citation>Whyte EM, Lenze EJ, Butters M, Skidmore E, Koenig K, Dew MA, Penrod L, Mulsant BH, Pollock BG, Cabacungan L, Reynolds CF 3rd, Munin MC. An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. Cerebrovasc Dis. 2008;26(3):317-21. doi: 10.1159/000149580. Epub 2008 Jul 31.</citation>
    <PMID>18667813</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 22, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ellen Whyte</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>donepezil</keyword>
  <keyword>recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

